Brian Mueller - 31 Dec 2025 Form 5 Insider Report for BIOMARIN PHARMACEUTICAL INC (BMRN)

Reporting relationship: EVP, Chief Financial Officer
Issuer ticker: BMRN
Reported as of: 31 Dec 2025
Net transaction value: +$20,301
SEC form: 5
Accepted by SEC: 13 Feb 2026, 19:01:49 UTC
Prior SEC filing: 18 Mar 2025
Next SEC filing: 26 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Tae Sang Yoo, Attorney-in-Fact

Key filing fact

Brian Mueller filed Form 5 for BIOMARIN PHARMACEUTICAL INC (BMRN) on 13 Feb 2026.

Key facts

This page summarizes Brian Mueller's Form 5 filing for BIOMARIN PHARMACEUTICAL INC (BMRN).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 13 Feb 2026, 19:01.

Change

Previous filing in this sequence was filed on 18 Mar 2025.
Current net transaction value: +$20,301.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 5 disclosures.

View source filing

Reporting Owners (1)

CIK 0001514980 Primary reporting owner

Mueller Brian

Relationship: EVP, Chief Financial Officer
Address: C/O BIOMARIN PHARMACEUTICAL INC., 770 LINDARO STREET, SAN RAFAEL
Signature: /s/ Tae Sang Yoo, Attorney-in-Fact
Signature date: 13 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BMRN transaction

Common Stock

Award

Transaction value: $20,301
Shares: +375
Change %: +0.38%
Price: $54.14
Shares after: 100,156
Date: 30 Apr 2025
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents the shares acquired by the reporting person on April 30, 2025, pursuant to the issuer's Employee Stock Purchase Plan.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .